Two-Drug HIV Regimen Gains FDA Approval - Summary - MDSpire
FDA & Government News

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

Share

The FDA has approved doravirine/islatravir (IDVYNSO) as a once-daily oral alternative for adults with virologically suppressed HIV-1, marking a significant development in antiretroviral therapy. This approval is based on Phase 3 trial results showing that the new regimen is noninferior in efficacy and safety compared to standard treatments, with approximately 92% of patients achieving viral suppression at 48 weeks. DOR/ISL offers a tenofovir-free option and is valuable for patients needing simplified treatment strategies, especially those with additional health concerns.

Original Source(s)

Two-Drug HIV Regimen Gains FDA Approval

  • by Kathryn Wighton

  • April 21, 2026

Related Content

Varicella Pneumonia Requires IV Acyclovir

Case highlights need for early intravenous antiviral treatment in adults with rash and hypoxia

A Reliable Cold Chain is a Health Equity Issue

Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines

Are Respiratory Deaths Underreported?

Postmortem testing reveals gaps in respiratory virus diagnosis

  • April 21, 2026

  • 3 min